Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Major Shareholder Samsara Biocapital Gp, Llc Purchases 600,000 Shares

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) major shareholder Samsara Biocapital Gp, Llc purchased 600,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were acquired at an average price of $13.50 per share, for a total transaction of $8,100,000.00. Following the completion of the transaction, the insider now directly owns 5,674,916 shares of the company’s stock, valued at $76,611,366. The trade was a 11.82 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Mineralys Therapeutics Price Performance

Shares of MLYS stock traded down $0.03 during trading hours on Monday, hitting $14.22. The company had a trading volume of 636,352 shares, compared to its average volume of 301,891. The company’s fifty day moving average is $10.45 and its 200 day moving average is $11.94. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $18.29. The stock has a market capitalization of $708.67 million, a PE ratio of -3.91 and a beta of 1.50.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.00) by $0.02. Equities analysts forecast that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Institutional Investors Weigh In On Mineralys Therapeutics

Large investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets purchased a new stake in shares of Mineralys Therapeutics in the 4th quarter valued at approximately $48,000. ProShare Advisors LLC purchased a new stake in shares of Mineralys Therapeutics in the 4th quarter valued at approximately $128,000. China Universal Asset Management Co. Ltd. increased its position in shares of Mineralys Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company’s stock valued at $130,000 after purchasing an additional 989 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new position in shares of Mineralys Therapeutics in the 4th quarter valued at $145,000. Finally, PDT Partners LLC acquired a new position in shares of Mineralys Therapeutics in the 3rd quarter valued at $148,000. 84.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Monday, March 10th. The Goldman Sachs Group lowered their price target on shares of Mineralys Therapeutics from $28.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Finally, Guggenheim restated a “buy” rating on shares of Mineralys Therapeutics in a research report on Monday, February 24th.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.